Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Highlights at SABCS 2021 for basic science and early-phase clinical trials

Bora Lim • 9 Dec 2021
SABCS 2021
Breast Cancer

Bora Lim, MD, Baylor College of Medicine, Houston, TX, discusses the highlights of SABCS 2021 for basic science, including the increased interest from clinicians in basic science discoveries due to the shorter timeframe between these early discoveries and a new therapy or assay appearing in the clinic. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Bora Lim

HIF-2α as an alternate therapeutic target in ER+ breast cancer
1:17
HIF-2α as an alternate therapeutic target in ER+ breast cancer
Bora Lim • 12 Dec 2024
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
2:46
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
Bora Lim • 12 Dec 2024
LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer
1:57
LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer
Bora Lim • 12 Dec 2024
Single-cell genomics and proteogenomics in cancer
1:49
Single-cell genomics and proteogenomics in cancer
Bora Lim • 9 Dec 2021

Related Videos

AIUR: surgical glove compression for paclitaxel-induced neuropathy in breast cancer
4:38
AIUR: surgical glove compression for paclitaxel-induced neuropathy in breast cancer
Young-Joon Kang • 25 Oct 2026
How can genomic assays guide treatment in HR+/HER2- breast cancer?
1:26
How can genomic assays guide treatment in HR+/HER2- breast cancer?
Kevin Kalinsky • 25 Oct 2026
Disease control and patient-reported quality of life in the ASCENT-04 trial
0:56
Disease control and patient-reported quality of life in the ASCENT-04 trial
Kevin Kalinsky • 25 Oct 2026
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
1:02
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
Kevin Kalinsky • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals